We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Solid State NMR Reveals Heat Shock Protein's Molecular Structure

By LabMedica International staff writers
Posted on 26 Oct 2015
A team of German proteomics researchers has established the molecular structure of the small heat shock protein alpha-B-crystallin, a finding that is expected to aid in the search for drugs to treat illnesses such as Alzheimer's disease, which are characterized by toxic protein clumping.

Heat shock proteins (HSP) are a family of proteins—of which alpha-B-crystallin is a member—that are produced by cells in response to exposure to stressful conditions. More...
They were first described in relation to heat shock, but are now known to also be expressed during other types of stress including exposure to cold, UV light, and during wound healing or tissue remodeling. Many members of this group perform a chaperone function by stabilizing new proteins to ensure correct folding or by helping to refold proteins that were damaged by cell stress.

Mechanistic details of human alpha-B-crystallin, particularly in its client-bound state, have been difficult to obtain, owing to the high molecular weight and the heterogeneity of these complexes.

Investigators at the Technical University of Munich (Germany) and the Helmholtz Zentrum Muenchen (Munich, Germany) used state-of-the-art solid-state NMR (nuclear magnetic resonance) spectroscopy to study the structure of alpha-B-crystallin bound to Alzheimer's disease Abeta1–40 peptide and, in a separate study, to the enzyme lysozyme.

They reported in the October 12, 2015, online edition of the journal Nature Structural Molecular Biology that the alpha-B-crystallin complex was assembled from asymmetric building blocks. Interaction studies demonstrated that the fibril-forming Alzheimer's disease Abeta1–40 peptide preferentially bound to a hydrophobic edge of the central beta-sandwich of alpha-B-crystallin. In contrast, the amorphously aggregating client lysozyme was captured by the partially disordered N-terminal domain of alpha-B-crystallin. These results implied that alpha-B-crystallin used its inherent structural plasticity to expose distinct binding interfaces and thus interact with a wide range of structurally variable clients.

Senior author Dr. Bernd Reif, professor of chemistry at the Technical University of Munich, said, "Alpha-B-crystallin exists in various different forms comprising 24, 28, or 32 subunits that are permanently being swapped. In addition, it has a large molecular weight. These factors make structure analysis very difficult."

Related Links:

Technical University of Munich
Helmholtz Zentrum Muenchen



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
BKE-B
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.